Management of mini-cardiopulmonary bypass devices: Is it worth the energy?

Current Opinion in Anaesthesiology

Volumn 22, Issue 1, 2009, Pages 78-83

  Ranucci, Marco ^a,b   Castelvecchio, Serenella ^a  

^a IRCCS   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Transfusions

Indexed keywords

ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEMODILUTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; META ANALYSIS; OFF PUMP SURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW;

BLOOD PHYSIOLOGICAL PHENOMENA; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS, OFF-PUMP; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 62349124110     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32831a408e     Document Type: Review

References (65)

1. Fukutomi M, Kobayashi S, Niwaya K, et al. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment. Artif Organs 1996; 20:767-776.
2. Rubens FD, Nathan H, Labow R, et al. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann Thorac Surg 2005; 79:655-665.
3. Shimamoto A, Kanemitsu S, Fujinaga K, et al. Biocompatibility of silicone-coated oxygenator in cardiopulmonary bypass. Ann Thorac Surg 2000; 69:115-120.
4. Ueyama K, Nishimura K, Nishina T, et al. PMEA coating of pump circuit and oxygenator may attenuate the early systemic inflammatory response in cardiopulmonary bypass surgery. ASAIO J 2004; 50:369-372.
5. Baufreton C, Moczar M, Intrator L, et al. Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits. Perfusion 1998; 13:419-427.
6. Hamada Y, Kawachi K, Nakata T, et al. Antiinflammatory effect of heparin-coated circuits with leukocyte-depleting filters in coronary bypass surgery. Artif Organs 2001; 25:1004-1008.
7. Pekna M, Borowiec J, Fagerhol MK, et al. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1994; 28:5-11.
8. Baufreton C, Jansen PG, Le Besnerais P1 et al. Hepann coating with aprotinin reduces blood activation during coronary artery operations. Ann Thorac Surg 1997; 63:50-56.
9. Belboul A, al-Khaja N. Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery. Perfusion 1997; 12:385-391.
10. Borowiec J, Bagge L, Saldeen T, Thelin S. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits. Thorac Cardiovasc Surg 1997; 45:163-167.
11. Fujita M, Ishihara M, Ono K, et al. Adsorption of inflammatory cytokines using a heparin-coated extracorporeal circuit. Artif Organs 2002; 26:1020-1025.
12. Ikuta T, Fujii H, Shibata T, et al. A new poly-2- methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy. Ann Thorac Surg 2004; 77:1678-1683.
13. Mollnes TE, Videm V, Gotze O, et al. Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin. Ann Thorac Surg 1991; 52:92-97.
14. Palanzo DA, Zarro DL, Manley NJ, et al. Effect of surface coating on platelet count drop during cardiopulmonary bypass. Perfusion 1999; 14:195-200.
15. Tamim M, Demircin M, Guvener M, et al. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass. Panminerva Med 1999; 41:193-198.
16. Tanaka H, Oshiyama T, Narisawa T, et al. Clinical study of biocompatibility between open and closed heparin-coated cardiopulmonary bypass circuits. J Artif Organs 2003; 6:245-252.
17. van der Kamp KW, van Oeveren W. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery. Int J Artif Organs 1993; 16:836-842.
18. Zimmermann AK, Weber N, Aebert H, et al. Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators. J Biomed Mater Res B Appl Biomater 2007; 80:433-439.
19. Barstad RM, Ovrum E, Ringdal MA, et al. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haematol 1996; 94:517-525.
20. Borowiec J, Thelin S, Bagge L, et al. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. J Thorac Cardiovasc Surg 1992; 104:642-647.
21. Borowiec JW, Hagman L, Totterman TH, et al. Circulating cytokines and granulocyte-derived enzymes during complex heart surgery. A clinical study with special reference to heparin-coating of cardiopulmonary bypass circuits. Scand J Thorac Cardiovasc Surg 1995; 29:167-174.
22. Ereth MH, Nuttall GA, Clarke SH, et al. Biocompatibility of trillium biopassive surface-coated oxygenator versus uncoated oxygenator during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2001; 15:545-550. [Discussion 539-541].
23. Gu YJ, van Oeveren W, Akkerman C, et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55:917-922.
24. Nilsson L, Peterson C, Venge P, et al. Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating. Ann Thorac Surg 1995; 59:713-716.
25. Spiess BD, Vocelka C, Cochran RP, et al. Heparin-coated bypass circuits (carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery. J Cardiothorao Vasc Anesth 1998; 12:299-304.
26. te Velthuis H, Baufreton C, Jansen PG, et al. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovasc Surg 1997; 114:117-122.
27. Defraigne JO, Pincemail J, Larbuisson R, et al. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg 2000; 69:1084-1091.
28. van den Goor JM, van Oeveren W, Rutten PM, et al. Adhesion of thrombotic components to the surface of a clinically used oxygenator is not affected by trillium coating. Perfusion 2006; 21:165-172.
29. van den Goor J, Nieuwland R, van den Brink A, et al. Reduced complement activation during cardiopulmonary bypass does not affect the postoperative acute phase response. Eur J Cardiothorac Surg 2004; 26:926-931.
30. Cazzaniga A, Ranucci M, Isgro G, et al. Trillium biopassive surface: a new biocompatible treatment for extracorporeal circulation circuits. Int J Artif Organs 2000; 23:319-324.
31. Horton SB, Butt WW, Mullaly RJ, et al. IL-6 and IL-8 levels after cardiopulmonary bypass are not affected by surface coating. Ann Thorac Surg 1999; 68:1751-1755.
32. Fosse E, Thelin S, Svennevig JL, et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study. Eur J Cardiothorac Surg 1997; 11:320-327.
33. Gorman RC, Ziats N, Rao AK, et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass, J Thorac Cardiovasc Surg 1996; 111:1, 11 [discussion 11-12].
34. Mariani MA, Gu YJ, Boonstra PW, et al. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg 1999; 67:1370-1375.
35. Aldea GS, Soltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002; 123:742-755.
36. de Haan J, Boonstra PW, Tabuchi N, et al. Retransfusion of thoracic wound blood during heart surgery obscures biocompatibility of the extracorporeal circuit. J Thorac Cardiovasc Surg 1996; 111:272-275.
37. de Haan J, Schönberger J, Haan J, et al. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106:1017-1023.
38. McCarthy PM, Yared JP, Foster RC, et al. A prospective randomized trial of duraflo II heparin-coated circuits in cardiac reoperations. Ann Thorac Surg 1999; 67:1268-1273.
39. Huybregts RAJM, Morariu AM, Rakhorst G, et al. Attenuated renal and intestinal injury after use of a mini-cardiopulmonary bypass system. Ann Thorac Surg 2007; 83:1 760-1767. A RCT demonstrating a better renal function and lower transfusion rate in patients treated with mini-CPB.
40. Abdel-Rahman U, Ozaslan F, Risteski PS, et al. Initial experience with a minimized extracorporeal bypass system: is there a clinical benefit? Ann Thorac Surg 2005; 80:238-244.
41. Wippermann J, Albes JM, Hartrumpf M, et al. Comparison of minimally invasive closed circuit extracorporeal circulation with conventional cardiopulmonary bypass and with off-pump technique in CABG patients: selected parameters of coagulation and inflammatory system. Eur J Cardiothorac Surg 2005; 28:127-132.
42. Fromes Y, Gaillard D, Ponzio O, et al. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg 2002; 22:527-533.
43. Kamiya H, Kofidis T, Haverich A, Klima U. Preliminary experience with the miniextracorporeal circulation system (Medtronic resting heart system). Interact Cardiovasc Thorac Surg 2006; 5:680-682.
44. Remadi JP, Marticho P, Butoi I, et al. Clinical experience with the miniextracorporeal circulation system: an evolution or a revolution? Ann Thorac Surg 2004; 77:2172-2176.
45. Mulholland JW, Anderson JR, Yarham GJ, et al. Miniature cardiopulmonary bypass: the Hammersmith experience. Perfusion 2007; 22:161-166.
46. Wiesenack C, Liebold A, Philipp A, et al. Four years' experience with a miniaturized extracorporeal circulation system and its influence on clinical outcome. Artif Organs 2004; 28:1082-1088.
47. Immer FF, Pirovino C, Gygax E, et al. Minimal versus conventional cardiopulmonary bypass: assessment of intraoperative myocardtal damage in coronary bypass surgery. Eur J Cardiothorac Surg 2005; 28:701-704.
48. Agati S, Ciccarello G, Trimarchi ES, et al. Extracorporeal circulation optimized: a pilot study. Artif Organs 2007; 31:377-383. This retrospective study highlights the need for an intensive training program for perfusionists, anesthesiologists, and surgeons involved in mini-CPB use.
49. Ti LK, Goh B-L, Wong P-S, et al. Comparison of mini-cardiopulmonary bypass system with air-purge device to conventional bypass system. Ann Thorac Surg 2008; 85:994-1001. This retrospective study denies a better outcome in patients treated with mini-CPB.
50. Ranucci M, Isgrò G. Minimally invasive cardiopulmonary bypass: does it really change the outcome? Crit Care 2007; 11:R45. The largest study on mini-CPB. More than 1600 patients treated with custom-made mini-CPB compared with a propensity-matched control group. This study demonstrates a better outcome in terms of postoperative atrial fibrillation rate, ventricular arrhythmias, peripheral thromboembolic rates, and a better renal function accompanied by shorter ICU and hospital stays.
51. Remadi JP, Rakotoarivello 2, Marticho P, et al. Aortic valve replacement with the minimal extracorporeal circulation (Jostra MECC System) versus standard cardiopulmonary bypass: a randomized prospective trial. J Cardiothorac Vasc Surg 2004; 128:436-441.
52. Nollert G, Schwabenland I, Maktav D, et al. Miniaturized cardiopulmonary bypass in coronary artery bypass surgery: marginal impact on inflammation and coagulation but loss of safety margins. Ann Thorac Surg 2005; 80:2326-2332.
53. Beghi C, Nicolini F, Agostinelli A, et al. Mini-cardiopulmonary bypass system: results of a prospective randomized study. Ann Thorac Surg 2006; 81:1396-1400.
54. Remadi JP, Rakotoarivelo Z, Marticho P, Benamar A. Prospective randomized study comparing coronary artery bypass grafting with the new mini-extra-corporeal circulation Jostra System or with a standard cardiopulmonary bypass. Am Heart J 2006; 151:198.e1-198.e7.
55. Perthel M, El-Ayoubi L, Bendisch A, et al. Clinical advantages of using mini-bypass systems in terms of blood product use, postoperative bleeding and air entrainment: an in vivo clinical perspective. Eur J Cardiothor Surg 2007; 31:1070-1075. This RCT demonstrates an important preservation of the hematocrit during CPB, with a significant reduction in transfusional needs in patients treated with a mini-CPB.
56. Castiglioni A, Verzini A, Pappalardo F, et al. Minimally invasive closed circuit versus standard extracorporeal circulation for aortic valve replacement. Ann Thorac Surg 2007; 83:586-591. A RCT confirming a containment in transfusion rate in mini-CPB group.
57. Mazzei V, Nasso G, Salamone G, et al. Prospective randomized comparison of coronary bypass grafting with minimal extracorporeal circulation system (MECC) versus off-pump coronary surgery. Circulation 2007; 116:1761-1767. A large RCT which demonstrates that patients treated with mini-CPB have a postoperative outcome comparable to off-pump coronary patients.
58. Habib RH, Zacharias A, Schwann TA, et al. Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed? J Thorac Cardiovasc Surg 2003; 125:1438-1450.
59. Swaminathan M, Phillips-Bute BG, Conlon PJ, et al. The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery. Ann Thorac Surg 2003; 76:784-792.
60. Karkouti K, Beattie WS, Wijeysundera DN, et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg 2005; 129:391-400.
61. Ranucci M, Romitti F, Isgrò G, et al. Oxygen delivery during cardiopulmonary bypass and acute renal failure following coronary operations. Ann Thorac Surg 2005; 80:2213-2220.
62. Engoren MC, Habib RH, Zacharias A, et al. Effect of blood transfusions on long-term survival after cardiac operation. Ann Thorac Surg 2002; 74:1880-1886.
63. Leal-Noval SR, Rincón-Ferrari MD, García-Curiel A, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001; 119:1461-1468.
64. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83:27-86.
65. Rubens FD, Boodhwani M, Mesana T, et al. The cardiotomy trial. A randomized, double-blind study to assess the effect of processing of shed blood during cardiopulmonary bypass on transfusion and neurocognitive function. Circulation 2007; 116 (Suppl 1):I-89-I-97. This study introduces the concern that routine intraoperative blood processing may deteriorate the postoperative outcome.